Labiotech.eu

Startup Scout 2 Mar 2018

This Spanish Biotech Is Developing Stem-Cell Targeted Leukemia Treatments

This week, we’re in Barcelona, Spain, to visit Leukos Biotech, whose goal is to develop new treatments and diagnostic tools for Leukaemia. Mission: Founded in 2015 as a spin-off from the Josep Carreras Leukaemia Research Institute (IJC), Leukos Biotech has raised €3.5M in funding and has identified a new therapeutic target against leukemic stem cells in acute […]

March 2, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 1 Mar 2018

Biosensors Bring HIV Test to Patients for Instant Results

A report on the use of biosensors in molecular disease diagnostics states the technology could significantly reduce the spread of HIV. A report by Cambridge-based IDTechEx analyzed important trends in the field of medical biosensors. Their results suggest the technology could reduce the spread of HIV and sexually transmitted diseases in general by cutting the time taken to send tests to a […]

March 1, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 1 Mar 2018

Doudna and Charpentier Get Second CRISPR Patent in Europe

Just a month after the European Patent Office revoked a CRISPR patent from the competitors of Doudna and Charpentier, they have been granted a second patent that covers a new form of the popular gene editing tool. The European Patent Office has granted CRISPR co-inventor Emmanuelle Charpentier, together with the University of California and the University […]

March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 1 Mar 2018

Could This Parisian Biotech Startup’s Cancer Treatment Compete With Merck and Novartis?

Stimunity, a Parisian biotech, secured a 2M€ seed investment to develop a cancer treatment that could compete with that of big players such as Merck and Novartis. Stimunity is a preclinical-stage startup company which develops drugs targeting a new cell signalling pathway to treat cancer. The company secured funding from Portage, a US-Canadian firm that […]

March 1, 2018 - 3 minutesmins - By Alexander Burik

More News! 1 Mar 2018

Just a Single Dose of this Drug Boosts the Survival of Heart Failure Patients

Berlin Cures’ drug fights off self-reactive antibodies that are associated with 80% of heart failure cases to improve heart function and patient survival. Berlin Cures was founded in 2014 to make use of research being carried out at Charité Medical University and the Max-Delbrueck-Center in Berlin. The biotech has achieved promising clinical data that suggests its first […]

March 1, 2018 - 3 minutesmins - By Alex Dale

Idorsia Actelion Spin Off Jean Paul Clozel CEO

News and Trends 1 Mar 2018

How is Actelion Spin-Off Idorsia Doing One Year Later?

Actelion’s spin-off Idorsia was blessed with a large pipeline and a healthy bank balance. How has the biotech’s first year of business gone? Just over a year ago, Actelion, the largest biotech in Europe at the time, was snapped up by Johnson & Johnson for a massive €27.9Bn. “This deal is unique: J&J gets its […]

March 1, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 28 Feb 2018

Yet Another Checkpoint Inhibitor Goes to Trial with Bavarian Nordic’s Cancer Vaccine

Bavarian Nordic and AstraZeneca collaborate on a treatment that uses a cancer vaccine along with a checkpoint inhibitor to treat colorectal and pancreatic cancer. Notably, this is the third checkpoint inhibitor to be tested with Bavarian Nordic’s vaccine. A Phase I/II trial will evaluate the safety and efficacy of using Bavarian Nordic’s cancer vaccine CV301 in […]

February 28, 2018 - 3 minutesmins - By Alexander Burik

novo holdings antibiotic resistance fight 1

News and Trends 28 Feb 2018

Novo Holdings Pumps €135M into New Antibiotic Development to Fight Resistance

Novo Holdings has launched a $165M (€135M) impact fund to support companies that are developing new drugs to overcome antibiotic resistance. Novo Holdings manages the assets of the Novo Nordisk Foundation, which invests money in companies that are working on scientific, humanitarian, and social projects. The company has launched a fund to develop new treatments for infections […]

February 28, 2018 - 3 minutesmins - By Alex Dale

More News! 28 Feb 2018

Could A More Precise CRISPR/Cas9 System Treat Huntington’s Disease?

Polish researchers tested a new variant of CRISPR/Cas9 that increases the gene-editing system’s precision in targeting specific DNA sequences, such as the gene responsible for Huntington’s disease. CRISPR/Cas9 offers a means of editing genes by essentially ‘cutting and pasting’ sequences of DNA. A group of researchers at the Institute of Bioorganic Chemistry in Poland has developed […]

February 28, 2018 - 3 minutesmins - By Alexander Burik

News and Trends 28 Feb 2018

Now We Know How the Brain Controls Pain, Better Analgesia Should Be on the Way

Researchers at the University of Cambridge believe that they have found the region of the brain that is responsible for pain relief, which should help future drug development efforts. Scientists at the University of Cambridge have identified the area of the brain that is responsible for pain relief, which could boost the development of alternative […]

February 28, 2018 - 4 minutesmins - By Alex Dale

News and Trends 28 Feb 2018

Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases?

Rare diseases affect fewer than 1 in 2,000 people in Europe and less than 200,000 Americans at any given time. A lack of financial incentive has put pharma off but biotechs are keen to step in and develop treatments and cures. Over 6,000 rare diseases affect up to 30 million people in the EU alone, which highlights […]

February 28, 2018 - 8 minutesmins - By Alex Dale

News and Trends 27 Feb 2018

This Small Molecule Protects the Muscles of Patients With Duchenne Muscular Dystrophy

Summit Therapeutics’ treatment for the devastating disease, Duchenne muscular dystrophy, reduces inflammation, which could protect muscle fibers from damage. Summit Therapeutics focuses on the development of treatments that can help patients suffering from diseases that currently lack options. The biotech has reported Phase II results for its drug for the genetic disease, Duchenne muscular dystrophy […]

February 27, 2018 - 3 minutesmins - By Alex Dale

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

This Spanish Biotech Is Developing Stem-Cell Targeted Leukemia Treatments

Biosensors Bring HIV Test to Patients for Instant Results

Doudna and Charpentier Get Second CRISPR Patent in Europe

Could This Parisian Biotech Startup’s Cancer Treatment Compete With Merck and Novartis?

Just a Single Dose of this Drug Boosts the Survival of Heart Failure Patients

How is Actelion Spin-Off Idorsia Doing One Year Later?

Yet Another Checkpoint Inhibitor Goes to Trial with Bavarian Nordic’s Cancer Vaccine

Novo Holdings Pumps €135M into New Antibiotic Development to Fight Resistance

Could A More Precise CRISPR/Cas9 System Treat Huntington’s Disease?

Now We Know How the Brain Controls Pain, Better Analgesia Should Be on the Way

Like Finding a Needle in a Haystack: How Are Biotechs Fighting Rare Diseases?

This Small Molecule Protects the Muscles of Patients With Duchenne Muscular Dystrophy

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!